New therapies for the treatment of heart failure: a summary of recent accomplishments

References

• BraunwaldEResearch advances in heart failure: a compendiumCirc Res2013113663364523888056
   PubMed Web of Science ®Google Scholar
• BenjaminEJBlahaMJChiuveSEAmerican Heart Association Statistics Committee and Stroke Statistics Subcommittee, 2017. Heart Disease and Stroke Statistics-2017 Update: a report from the American Heart AssociationCirculation2017135e146e60328122885
   PubMed Web of Science ®Google Scholar
• PonikowskiPVoorsAAAnkerSDESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESCEur Heart J2016201618891975
   Google Scholar
• GhoshRKBanerjeeKTummalaRBallSRavakhahKGuptaASerelaxin in acute heart failure: most recent update on clinical and preclinical evidenceCardiovasc Ther2017351556327727514
   PubMed Web of Science ®Google Scholar
• AljundiAHSMohammedSFKPatelAInotropic agents use in patients hospitalized with acute decompensated heart failure: a retrospective analysis from a 22-year registry in a Middle-Eastern Country (1991–2013)BMC Cardiovasc Disord20161614726892533
   PubMed Web of Science ®Google Scholar
• TariqSAronowWUse of inotropic agents in treatment of systolic heart failureInt J Mol Sci20151612290602906826690127
   PubMed Web of Science ®Google Scholar
• GreenbergBNovel therapies for heart failure-where do they stand?Circ J18912016801882
   Google Scholar
• TeerlinkJRFelkerGMMcmurrayJJVAcute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: The ATOMIC-AHF StudyJ Am Coll Cardiol201667121444145527012405
   PubMed Web of Science ®Google Scholar
• Planelles-HerreroVJHartmanJJRobert-PaganinJMalikFIHoudusseAMechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbilNat Commun20178119028775348
   PubMed Web of Science ®Google Scholar
• HashemSTibertiMForniliAAllosteric modulation of cardiac myosin dynamics by omecamtiv mecarbilPLoS Comput Biol20171311e100582629108014
   PubMed Web of Science ®Google Scholar
• StarlingRCCardiac myosin activators for the treatment of heart failure stop now or push aheadJ Am Coll Cardiol201667121456145827012406
   PubMed Web of Science ®Google Scholar
• GassanovNBiesenbachECaglayanENatriuretic peptides in therapy for decompensated heart failureEur J Clin Pharmacol201268322323021901345
   PubMed Web of Science ®Google Scholar
• PotterLRAbbey-HoschSDickeyDMNatriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functionsEndocr Rev2006271477216291870
   PubMed Web of Science ®Google Scholar
• AnkerSDPonikowskiPMitrovicVPeacockWFFilippatosGUlaritide for the treatment of acute decompensated heart failure: from preclinical to clinical studiesEur Heart J2015361271572325670819
   PubMed Web of Science ®Google Scholar
• BestleMHOlsenNVChristensenPJensenBVBiePCardiovascular, endocrine, and renal effects of urodilatin in normal humansAm J Physiol19992763 Pt 2R684R69510070128
   PubMedGoogle Scholar
• SchmittMGunaruwanPPayneNEffects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failureArterioscler Thromb Vasc Biol200424591191715001459
   PubMed Web of Science ®Google Scholar
• SaxenhoferHRaselliAWeidmannPUrodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in menAm J Physiol19902595 Pt 2F832F8382146885
   PubMed Web of Science ®Google Scholar
• KentschMLudwigDDrummerCGerzerRMüller-EschGHaemodynamic and renal effects of urodilatin in healthy volunteersEur J Clin Invest19922253193251317296
   PubMed Web of Science ®Google Scholar
• KentschMLudwigDDrummerCGerzerRMüller-EschGHaemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failureEur J Clin Invest199222106626691333960
   PubMed Web of Science ®Google Scholar
• MitrovicVLüssHNitscheKEffects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trialAm Heart J20051506123916338265
   PubMed Web of Science ®Google Scholar
• MitrovicVSeferovicPMSimeunovicDHaemodynamic and clinical effects of ularitide in decompensated heart failureEur Heart J200627232823283217074775
   PubMed Web of Science ®Google Scholar
• PackerMHolcombRAbrahamWTRationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failureEur J Heart Fail201719567368127862700
   PubMed Web of Science ®Google Scholar
• PackerMO’ConnorCMcmurrayJJVEffect of ularitide on cardiovascular mortality in acute heart failureN Engl J Med2017376201956196428402745
   PubMed Web of Science ®Google Scholar
• PackerMShort- and long-term effect of immediate vasodilator therapy in acute decompensated heart failurePresented at American Heart Association Scientific Session11132016New Orleans, LA
   Google Scholar
• BathgateRAHallsMLvan der WesthuizenETCallanderGEKocanMSummersRJRelaxin family peptides and their receptorsPhysiol Rev201393140548023303914
   PubMed Web of Science ®Google Scholar
• SmithMCDanielsonLAConradKPDavisonJMInfluence of recombinant human relaxin on renal hemodynamics in healthy volunteersJ Am Soc Nephrol200617113192319717035617
   PubMed Web of Science ®Google Scholar
• DschietzigTTeichmanSUnemoriEIntravenous recombinant human relaxin in compensated heart failure: a safety, tol-erability, and pharmacodynamic trialJ Card Fail200915318219019327619
   PubMed Web of Science ®Google Scholar
• TeerlinkJRMetraMFelkerGMRelaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb studyThe Lancet2009373967314291439
   PubMed Web of Science ®Google Scholar
• TeerlinkJRCotterGDavisonBARELAXin in Acute Heart Failure (RELAX-AHF) InvestigatorsSerelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trialLancet2013381293923141816
   PubMed Web of Science ®Google Scholar
• SatoNLamCSTeerlinkJREvaluating the efficacy, safety, and tolerability of serelaxin when added to standard therapy in asian patients with acute heart failure: design and rationale of RELAX-AHF-ASIA trialJ Card Fail2017231637127825893
   PubMed Web of Science ®Google Scholar
• TeerlinkJRVoorsAAPonikowskiPSerelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 studyEur J Heart Fail201719680080928452195
   PubMed Web of Science ®Google Scholar
• TeerlinkJSerelaxin in acute heart failure presented at Heart Failure 2017 and the 4th World Congress on Acute Heart FailureParis, France29 April, 2017
   Google Scholar
• InomataTIkedaYKidaKEffects of additive tolvaptan vs. Increased furosemide on heart failure with diuretic resistance and renal impairment – results from the K-STAR studyCirc J2018821159167
   Web of Science ®Google Scholar
• PoseAAlmenarLGaviraJJBenefit of tolvaptan in the management of hyponatraemia in patients with diuretic-refractory congestive heart failure: the SEMI-SEC projectESC Heart Failure20174213013728451449
   PubMed Web of Science ®Google Scholar
• VinodPKrishnappaVChauvinAMKhareARainaRCardiorenal syndrome: role of arginine vasopressin and vaptans in heart failureCardiol Res201783879528725324
   PubMed Web of Science ®Google Scholar
• NomotoHSatohYKamiyamaMMechanisms of diuresis for acute decompensated heart failure by tolvaptanInt Heart J201758459360028701677
   PubMed Web of Science ®Google Scholar
• KinugawaKSatoNInomataTEfficacy and safety of tolvaptan in heart failure patients with volume overload – an Interim result of post-marketing surveillance in JapanCirc J20147884485224670835
   PubMed Web of Science ®Google Scholar
• SağSAydın KaderliAYıldızAUse of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatre-mia: The initial experience at a single-center in TurkeyTurk Kardiyol Dern Ars201745541542528694395
   PubMed Web of Science ®Google Scholar
• UemuraYShibataRTakemotoKSafety and efficacy of long-term use of tolvaptan in patients with heart failure and chronic kidney diseaseCirc J201781111736173828883217
   PubMed Web of Science ®Google Scholar
• AmbrosyAPKhanHUdelsonJEChanges in dyspnea status during hospitalization and postdischarge health-related quality of life in patients hospitalized for heart failure: findings from the EVEREST trialCirc Heart Fail201695e00245827140204
   PubMed Web of Science ®Google Scholar
• LópezBGonzálezAQuerejetaRLarmanMRábagoGDíezJAssociation of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failureHypertension201463348348924366078
   PubMed Web of Science ®Google Scholar
• CalabròPLimongelliGRieglerLNovel insights into the role of cardiotrophin-1 in cardiovascular diseasesJ Mol Cell Cardiol200946214214819059413
   PubMed Web of Science ®Google Scholar
• Abdul-GhaniMSuenCJiangBCardiotrophin 1 stimulates beneficial myogenic and vascular remodeling of the heartCell Research201727101195121528785017
   PubMed Web of Science ®Google Scholar
• RegisGPensaSBoselliDNovelliFPoliVUps and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signallingSemin Cell Dev Biol200819435135918620071
   PubMed Web of Science ®Google Scholar
• ObanaMMaedaMTakedaKTherapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarctionCirculation2010121568469120100971
   PubMed Web of Science ®Google Scholar
• Moreno-AliagaMJPérez-EcharriNMarcos-GómezBCardiotrophin-1 is a key regulator of glucose and lipid metabolismCell Metab201114224225321803294
   PubMed Web of Science ®Google Scholar
• WilliamsMLHataJASchroderJTargeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human heartsCirculation2004109131590159315051637
   PubMed Web of Science ®Google Scholar
• KarakikesIChaanineAHKangSTherapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodelingJ Am Heart Assoc201322e00007823612897
   PubMed Web of Science ®Google Scholar
• GanesanJRamanujamDSassiYMiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factorsCirculation2013127212097210623625957
   PubMed Web of Science ®Google Scholar
• JessupMGreenbergBManciniDCalcium upregulation by per-cutaneous administration of gene therapy in cardiac disease (CUPID)Circulation2011124330431321709064
   PubMed Web of Science ®Google Scholar
• ZseboKYaroshinskyARudyJJLong-Term Effects of AAV1/SERCA2a Gene Transfer in Patients With Severe Heart FailureCirculation Research2014114110110824065463
   PubMed Web of Science ®Google Scholar
• BeeriRChaputMGuerreroJLGene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitationCirc Heart Fail20103562763420634484
   PubMed Web of Science ®Google Scholar
• FishKMLadageDKawaseYAAV9.I-1c Delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodelingCirculation: Heart Failure20136231031723271792
   PubMed Web of Science ®Google Scholar
• HammoudiNIshikawaKHajjarRJAdeno-associated virus-mediated gene therapy in cardiovascular diseaseCurrent Opinion in Cardiology201530322823425783685
   PubMed Web of Science ®Google Scholar
• GreenbergBButlerJFelkerGMCalcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trialThe Lancet20163871002411781186
   PubMed Web of Science ®Google Scholar